MRI评估乳腺癌新辅助化疗后腋窝淋巴结状态的诊断效能:系统评价与Meta分析
该系统评价纳入21项研究共2875例乳腺癌患者,评估MRI在新辅助化疗后判断腋窝淋巴结状态的诊断效能。汇总敏感度0.63、特异度0.75、AUC 0.76,敏感度与特异度异质性均较高(I²分别为94.41%和88.97%)。作者认为MRI的诊断价值可能欠佳,需进一步研究确认。
要点
- MRI判断新辅助化疗后腋窝淋巴结状态的汇总敏感度0.63、特异度0.75、AUC 0.76。
- 初诊腋窝淋巴结阳性患者汇总敏感度0.64、特异度0.74。
- 敏感度异质性I²=94.41%、特异度异质性I²=88.97%,均大于50%。
核心结论
- MRI在评估乳腺癌患者新辅助化疗后腋窝淋巴结状态方面可能诊断价值欠佳,初诊腋窝淋巴结状态对其诊断效能影响不大,研究间存在较大异质性,需进一步研究确认。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Cochrane Library和Web of Science,纳入21项研究共2875例患者,采用QUADAS-2工具评估方法学质量,用STATA 12.0进行数据合并、异质性检验、亚组分析和敏感性分析。
诊断标准与关键数值
- 汇总敏感度0.63(95%CI 0.53-0.72)、特异度0.75(95%CI 0.68-0.81)、阳性似然比2.52(95%CI 1.98-3.19)、阴性似然比0.50(95%CI 0.39-0.63)、诊断比值比5.08(95%CI 3.38-7.63)、AUC 0.76(95%CI 0.72-0.79)。初诊腋窝淋巴结阳性患者汇总敏感度0.64(95%CI 0.53-0.75)、特异度0.74(95%CI 0.64-0.82)。
临床应用与阅片要点
- 作者认为MRI在评估乳腺癌新辅助化疗后腋窝淋巴结状态方面可能诊断价值欠佳;针对新辅助化疗后行MRI、使用DCE-MRI或低偏倚风险研究的敏感性分析结果与主要分析相似。
局限性
- 新辅助化疗方案不一致。
- 腋窝手术方式存在变异性。
- 缺乏MRI与手术之间的时间间隔信息。
- 敏感度异质性I²=94.41%、特异度异质性I²=88.97%,均大于50%。
- 需进一步研究确认上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This systematic review examined the diagnostic performance of magnetic resonance imaging (MRI) for assessing axillary lymph node status (ALNS) after neoadjuvant chemotherapy (NAC) in breast cancer patients.
METHODS: We searched PubMed, Embase, Cochrane Library, and Web of Science to identify relevant studies and used the QUADAS-2 tool to assess methodological quality of eligible studies. We used STATA version 12.0 to perform data pooling, heterogeneity testing, subgroup analysis, and sensitivity analysis.
RESULTS: For the 21 enrolled studies, including 2875 patients, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were respectively 0.63 (95% CI: 0.53-0.72), 0.75 (95% CI: 0.68-0.81), 2.52 (95% CI: 1.98-3.19), 0.50 (95% CI: 0.39-0.63), and 5.08 (95% CI: 3.38-7.63). The AUC was 0.76 (95% CI: 0.72-0.79). I2 values of sensitivity (I2 = 94.41%) and specificity (I2 = 88.97%) were both > 50%. For the initial positive ALN patients, the pooled sensitivity and specificity were 0.64 (95% CI: 0.53-0.75) and 0.74 (95% CI: 0.64-0.82), respectively. Sensitivity analyses by focusing on studies with MRI performed post-NAC, studies using DCE-MRI, or studies with low risk of bias showed similar results to the primary analyses.
CONCLUSION: MRI may have suboptimal diagnostic value in assessing ALNS after NAC for breast cancer patients. Due to the inconsistency of NAC regimens, the variability of axillary surgery, and the lack of time interval between MRI and surgery, further studies are needed to confirm our findings.
CLINICAL RELEVANCE STATEMENT: Our study provided the diagnostic value of MRI in assessing axillary lymph node status after neoadjuvant chemotherapy for breast cancer patients.
KEY POINTS: • MRI may have suboptimal diagnostic value in assessing axillary lymph node status after NAC for general breast cancer patients. • The initial axillary lymph node status has little impact on the diagnostic efficacy of MRI. • The substantial heterogeneity among studies highlights the need for further studies to provide more high-quality evidence in this field.
引用
- Li Z, Ma Q, Gao Y, et al. Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Eur Radiol. 2023. PMID: 37615764. doi:10.1007/s00330-023-10155-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。